Business Context and Reporting Period
Company: Aligos Therapeutics, Inc. (ALGS)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Aligos is a clinical-stage biotechnology company developing novel therapeutics for liver diseases (chronic Hepatitis B, MASH) and viral infections (Coronavirus). The company has no approved products and has not generated revenue from product sales.
Key Financial Metrics
| Metric | 2025 (in thousands) | 2024 (in thousands) |
|---|---|---|
| Total Revenue | $2,186 | $3,945 |
| Net Loss | $(24,193) | $(131,211) |
| Operating Expenses | $90,171 | $93,099 |
| Cash, Cash Equivalents & Short-term Investments | $77,800 | $56,900 |
| Accumulated Deficit | $(642,201) | $(618,008) |
| Stockholders' Equity | $53,545 | $(28,973) |
Note: The significant reduction in net loss for 2025 is primarily driven by a $60.2 million non-cash gain from the change in fair value of 2023 Common Warrants, compared to a $46.1 million loss in 2024.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by approximately 45% to $2.2 million, driven by the completion of a collaboration agreement with Merck in 2024 and the winding down of the collaboration portion of the Amoytop agreement in late 2025.
- Operating Expenses: Total operating expenses decreased slightly by 3% to $90.2 million. Research and Development (R&D) expenses remained relatively flat ($69.5 million vs. $70.3 million), while General and Administrative (G&A) expenses decreased by 9% to $20.7 million due to reduced legal and IP spend.
- Liquidity Improvement: Cash and investments increased to $77.8 million from $56.9 million, bolstered by a February 2025 private placement (PIPE) that generated $105.0 million in gross proceeds.
- Equity Position: The company moved from a stockholders' deficit of $(29.0) million in 2024 to positive equity of $53.5 million in 2025, largely due to the warrant fair value gain and new capital raises.
Guidance, Outlook, and Risks
Going Concern Warning
The independent auditors have included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern. Management expects existing cash resources to fund operations only into the third quarter of 2026. The company plans to raise additional capital through equity offerings, debt, or collaborations, but there is no assurance such funding will be available on acceptable terms.
Clinical Pipeline Outlook
- Pevifoscorvir sodium (HBV): Phase 2 B-SUPREME study is ongoing. First interim analysis expected in H1 2026; topline data expected in 2027.
- ALG-055009 (MASH/Obesity): Phase 2a HERALD study met primary endpoint. Company is evaluating out-licensing options to fund further development.
- ALG-097558 (Coronavirus): Phase 2 study ongoing. Development is partially funded by NIH/NIAID grants totaling approximately $15.3 million.
Key Risks
- Capital Needs: Failure to secure additional financing could force the company to delay, limit, or terminate product development.
- Regulatory Uncertainty: No products are approved; clinical trial outcomes are uncertain.
- Intellectual Property: Reliance on licensed IP from Emory University and KU Leuven, with significant milestone payment obligations (e.g., $9.0 million paid to Emory in 2025).
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for the next capital raise given the Q3 2026 liquidity horizon.
- Warrant Liability: Confirm the remaining liability for 2023 Common Warrants ($12.2 million) and the potential for future volatility in net income based on stock price fluctuations.
- Grant Funding: Assess the sustainability of the $15.3 million NIH/NIAID funding for the coronavirus program and any conditions attached.
- Milestone Obligations: Review upcoming development milestones under the Emory and KU Leuven agreements that could trigger significant cash outflows.
- Out-Licensing Strategy: Monitor progress on potential out-licensing deals for ALG-055009 to offset development costs.